Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

NCT06270316 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: AMT-191

Sponsor

UniQure Biopharma B.V.